Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Roche

Status and phase: Completed; Phase 3

Conditions: NMO Spectrum Disorder (NMOSD); Neuromyelitis Optica (NMO)

Treatments: Drug: Placebo; Drug: Baseline Treatment; Drug: Satralizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT02028884

BN40898

SA-307JG (Other Identifier)

2013-003752-21 (EudraCT Number)

Details and patient eligibility

About

The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in participants with NMO and NMOSD.

Enrollment: 85 patients

Sex: All

Ages: 12 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients must be diagnosed as having either neuromyelitis optica (NMO) or NMO spectrum disorder (NMOSD), defined as the following:

   1. NMO as defined by Wingerchuk et al. 2006 criteria (requires all of the following 3 criteria: I. Optic neuritis, II. Acute myelitis, III. At least two of three supportive criteria: Contiguous spinal cord lesion identified on a magnetic resonance imaging (MRI) scan extending over 3 vertebral segments; Brain MRI not meeting diagnostic criteria for multiple sclerosis (MS); NMO-IgG seropositive status)
   2. NMOSD as defined by either of the following Wingerchuk 2007 criteria with anti-AQP4 antibody (Ab) seropositive status at screening (i. Idiopathic single or recurrent events of longitudinally extensive myelitis [≥3 vertebral segment spinal cord MRI lesion]; ii. Optic neuritis: recurrent or simultaneous bilateral); For patients aged 12 to 17 years, a minimum of 4 patients should be positive for anti-AQP4Ab status at screening

2. Clinical evidence of at least 2 documented relapses (including first attack) in the last 2 years prior to screening, at least one of which has occurred in the 12 months prior to screening

3. EDSS score from 0 to 6.5 inclusive at screening

4. Age 12 to 74 years, inclusive at the time of informed consent

5. One of the following baseline treatments must be at stable dose as a monotherapy for 8 weeks prior to baseline: Azathioprine; Mycophenolate mofetil; Oral corticosteroids. For participants aged 12 to 17 years, either of the following baseline treatments for relapse prevention can be allowed: Azathioprine + oral corticosteroids; Mycophenolate mofetil + oral corticosteroids

6. Ability and willingness to provide written informed consent and to comply with the requirements of the protocol

For adolescents who may be enrolled after the end of the double-blind period, the inclusion criterion 2 is as follows (other criteria are same): Clinical evidence of at least 2 documented relapses (including first attack) prior to screening.

Exclusion criteria

Exclusion criteria related to previous or concomitant therapy:

1. Any previous treatment with IL-6 inhibitory therapy (e.g. tocilizumab), alemtuzumab, total body irradiation or bone marrow transplantation at any time

2. Any previous treatment with anti-CD20, eculizumab, belimumab, interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate within 6 months prior to baseline

3. Any previous treatment with anti-CD4, cladribine or mitoxantrone within 2 years prior to baseline

4. Treatment with any investigational agent within 3 months prior to baseline

   Exclusions for general safety:

5. Pregnancy or lactation

6. For patients of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier [patient or partner] in conjunction with a spermicidal product, contraceptive pill, patch, injectables, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug

7. Any surgical procedure (except for minor surgeries) within 4 weeks prior to baseline

8. Evidence of other demyelinating disease or progressive multifocal leukoencephalopathy (PML)

9. Evidence of serious uncontrolled concomitant diseases that may preclude patient participation, such as: other nervous system disease, cardiovascular disease, hematologic/hematopoiesis disease, respiratory disease, muscular disease, endocrine disease, renal/urologic disease, digestive system disease, congenital or acquired severe immunodeficiency

10. Known active infection (excluding fungal infections of nail beds or caries dentium) within 4 weeks prior to baseline

11. Evidence of chronic active hepatitis B or C

12. History of drug or alcohol abuse within 1 year prior to baseline

13. History of diverticulitis that, in the Investigator's opinion, may lead to increased risk of complications such as lower gastrointestinal perforation

14. Evidence of active tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection)

15. Evidence of active interstitial lung disease

16. Receipt of any live or live attenuated vaccine within 6 weeks prior to baseline

17. History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured)

18. History of severe allergic reaction to a biologic agent (e.g. shock, anaphylactic reactions)

19. Active suicidal ideation within 6 months prior to screening, or history of suicide attempt within 3 years prior to screening

20. Following laboratory abnormalities at screening*.

    1. White blood cells (WBC) <3.0 x10^3/microliter (μL)
    2. Absolute neutrophil count (ANC) <2.0 x10^3/μL
    3. Absolute lymphocyte count <0.5 x10^3/μL
    4. Platelet count <10 x 10^4/μL
    5. Aspartate aminotransferase (AST) or alanine aminotranferase (ALT) >1.5 times the upper limit of normal (ULN) * If retest is conducted, the last value of retest before randomization must meet study criteria.

For adolescents who may be enrolled after the end of the double-blind period, the annotation in the exclusion criterion 20 is as follows (other criteria are same): * If retest is conducted, the last value of retest before baseline must meet study criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

85 participants in 2 patient groups, including a placebo group

Satralizumab + Baseline Treatment

Experimental group

Description:

Participants randomized to this arm for the double-blind period will receive satralizumab in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.

Treatment:

Drug: Satralizumab

Drug: Baseline Treatment

Placebo + Baseline Treatment

Placebo Comparator group

Description:

Participants randomized to this arm for the double-blind period will receive placebo in addition to baseline treatment.The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.

Treatment:

Drug: Placebo

Drug: Baseline Treatment